Currently, there are 188.95M common shares owned by the public and among those 87.23M shares have been available to trade.
The company’s stock has a 5-day price change of -9.50% and 26.90% over the past three months. ALHC shares are trading 16.14% year to date (YTD), with the 12-month market performance up to 44.09% higher. It has a 12-month low price of $4.46 and touched a high of $12.36 over the same period. ALHC has an average intraday trading volume of 1.04 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.71%, 3.46%, and 32.62% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Alignment Healthcare Inc (NASDAQ: ALHC) shares accounts for 41.07% of the company’s 188.95M shares outstanding.
It has a market capitalization of $1.91B and a beta (3y monthly) value of 1.47. The earnings-per-share (ttm) stands at -$0.81. The company has a debt-to-equity ratio at 1.78. Price movements for the stock have been influenced by the stock’s volatility, which stands at 8.74% over the week and 7.66% over the month.
Earnings per share for the fiscal year are expected to increase by 14.78%, and 25.95% over the next financial year.
Looking at the support for the ALHC, a number of firms have released research notes about the stock. BofA Securities stated their Buy rating for the stock in a research note on May 30, 2024, with the firm’s price target at $7.75-$11. Robert W. Baird coverage for the Alignment Healthcare Inc (ALHC) stock in a research note released on May 30, 2024 offered a Outperform rating with a price target of $10. Piper Sandler was of a view on May 08, 2024 that the stock is Overweight, while Barclays gave the stock Underweight rating on March 06, 2024, issuing a price target of $4.50. Piper Sandler on their part issued Neutral rating on March 06, 2024.
